RxDoctor Payments Data

Rita Sharma, MD

Gynecology · Tucker, GANPI 1215035407

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Medtronic at 38.0% of the total. 2025 is the largest year on record at $1,378, 6.5 times the $213 reported in 2019.

$4,165in general payments, 2019–2025

Across 127 payments — averaging $32.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Coloplast$701
  • Astellas Pharma US Inc$417
  • Pfizer$237
  • Sumitomo Pharma America, Inc.$188
  • AbbVie$184
  • plus $855 from 18 others

What the payments were for

  • Travel & lodging$1,38133%
  • Food & beverage$2,49360%
  • Education$2225%
  • Gifts$692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,165 in reported general payments places this provider in the 85th percentile of 119 gynecology providers in Georgia.

See all gynecology providers in Georgia

Medicare billing

Part B allowed, 2024
$22,832
Medicare patients
78
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron35$31,506
PremarinEstrogens, Conjugated24$12,877
Estradiol87$4,299
Metronidazole27$113
Ciprofloxacin Hcl14$78
Fluconazole14$55
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$417$31,50635 claims
PfizerPremarin$237$12,87724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 119 gynecology providers in Georgia.

Other gynecology in Tucker

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →